<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001330" GROUP_ID="MS" ID="111399101411053693" MERGED_FROM="" MODIFIED="2008-09-18 10:04:37 +0200" MODIFIED_BY="Liliana Coco" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-09-11 11:14:43 +0200" MODIFIED_BY="Liliana Coco">
<TITLE>Aminopyridines for symptomatic treatment in multiple sclerosis</TITLE>
<CONTACT>
<PERSON ID="6361" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Alessandra</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Solari</LAST_NAME>
<SUFFIX/>
<POSITION>MD (Neurologist)</POSITION>
<EMAIL_1>solari@istituto-besta.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neuroepidemiology Unit</DEPARTMENT>
<ORGANISATION>Fondazione I.R.C.C.S. - Neurological Institute Carlo Besta</ORGANISATION>
<ADDRESS_1>Via Celoria 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20133</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-02-2394 2391</PHONE_1>
<PHONE_2/>
<FAX_1>+39-02-70638217</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-09-11 10:55:33 +0200" MODIFIED_BY="Liliana Coco">
<PERSON ID="6361" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Alessandra</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Solari</LAST_NAME>
<SUFFIX/>
<POSITION>MD (Neurologist)</POSITION>
<EMAIL_1>solari@istituto-besta.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neuroepidemiology Unit</DEPARTMENT>
<ORGANISATION>Fondazione I.R.C.C.S. - Neurological Institute Carlo Besta</ORGANISATION>
<ADDRESS_1>Via Celoria 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Milan</CITY>
<ZIP>20133</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-02-2394 2391</PHONE_1>
<PHONE_2/>
<FAX_1>+39-02-70638217</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9046" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Bernard</FIRST_NAME>
<MIDDLE_INITIALS>MJ</MIDDLE_INITIALS>
<LAST_NAME>Uitdehaag</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor of Neurology and Epidemiology</POSITION>
<EMAIL_1>bmj.uitdehaag@vumc.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology and Dept. of Clinical Epidemiology &amp; Biostatistics</DEPARTMENT>
<ORGANISATION>VU University Medical Centre</ORGANISATION>
<ADDRESS_1>P.O. Box 7057</ADDRESS_1>
<ADDRESS_2/>
<CITY>Amsterdam</CITY>
<ZIP>1007 MB</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>31-20-444 2834</PHONE_1>
<PHONE_2>31-20-444 4474</PHONE_2>
<FAX_1>31-20-444 2800</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14853" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giorgio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Giuliani</LAST_NAME>
<SUFFIX/>
<POSITION>Direttore U.O. Neurologia</POSITION>
<EMAIL_1>giulineu@libero.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medicina</DEPARTMENT>
<ORGANISATION>Ospedale di Macerata</ORGANISATION>
<ADDRESS_1>Via Santa Lucia, 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Macerata</CITY>
<ZIP>62100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>339 4439350</PHONE_1>
<PHONE_2>071 33026</PHONE_2>
<FAX_1>0733 2572825</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14870" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Eugenio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pucci</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>eugenio_pucci@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>347-2304548</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>U.O. Neurologia - Ospedale di Macerata</DEPARTMENT>
<ORGANISATION>ASUR Marche - Zona Territoriale 9</ORGANISATION>
<ADDRESS_1>Via Santa Lucia, 3</ADDRESS_1>
<ADDRESS_2/>
<CITY>Macerata</CITY>
<ZIP>62100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-0733-257844</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14877" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Cristiana</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Taus</LAST_NAME>
<SUFFIX/>
<POSITION>Neurologist</POSITION>
<EMAIL_1>cristianataus@yahoo.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Unità Operativa di Neurologia</DEPARTMENT>
<ORGANISATION>Ospedale San Salvatore</ORGANISATION>
<ADDRESS_1>Piazzale Cinelli,4</ADDRESS_1>
<ADDRESS_2/>
<CITY>Pesaro</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39-0721-362390</PHONE_1>
<PHONE_2>+39-347-3652132</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-11 11:03:50 +0200" MODIFIED_BY="Liliana Coco">
<UP_TO_DATE>
<DATE DAY="29" MONTH="12" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="12" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="12" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-11 11:01:58 +0200" MODIFIED_BY="Liliana Coco">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="20" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-11 11:02:08 +0200" MODIFIED_BY="Liliana Coco">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-21 11:33:21 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="14" MONTH="12" YEAR="2004"/>
<DESCRIPTION>
<P>Searches were re-run</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-11 11:02:08 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="13" MONTH="12" YEAR="2004"/>
<DESCRIPTION>
<P>Conclusions not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="15" MONTH="7" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-21 11:30:54 +0200" MODIFIED_BY="Liliana Coco">
<DATE DAY="15" MONTH="7" YEAR="2002"/>
<DESCRIPTION>
<P>Searches were re-run</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-09-11 11:14:43 +0200" MODIFIED_BY="Liliana Coco">
<INTERNAL_SOURCES MODIFIED="2008-09-11 11:14:43 +0200" MODIFIED_BY="Liliana Coco">
<SOURCE MODIFIED="2008-09-11 11:14:43 +0200" MODIFIED_BY="Liliana Coco">
<NAME>Fondazione I.R.C.S.S. -Istituto Neurologico C. Besta</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-11 11:08:46 +0200" MODIFIED_BY="Liliana Coco">
<SUMMARY MODIFIED="2008-08-21 10:26:26 +0200" MODIFIED_BY="Liliana Coco">
<TITLE MODIFIED="2008-08-21 10:26:26 +0200" MODIFIED_BY="Liliana Coco">The effect of aminopyridine for the treatment of several symptoms in people with multiple sclerosis</TITLE>
<SUMMARY_BODY>
<P>Multiple sclerosis (MS) is a disease that affects young and middle-aged adults, causing different symptoms in individuals. It is caused by damage to the myelin sheaths (fibres that wrap around and protect the nerves and spinal cord). Potassium (a mineral) is important for nerve function, but may become too active when there is not enough myelin. Potassium blocking drugs (4-aminopyridine AP, and 3,4-daminopyridine DAP) may be able to improve nerve function in nerves without enough myelin. However, the review of trials found there is not enough evidence about the safety of these drugs or whether benefits are certain.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-26 12:48:34 +0200" MODIFIED_BY="Deirdre Beecher">
<ABS_BACKGROUND>
<P>The potassium channel blockers 4-aminopyridine (AP) and 3,4-diaminopyridine (DAP) increase nerve conduction in demyelinated nerve fibers, and have been proposed as a symptomatic therapy for people with multiple sclerosis (MS). </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy and safety of aminopyridines for neurological deficits in adults with MS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-08-26 12:48:34 +0200" MODIFIED_BY="Deirdre Beecher">
<P>We searched the Cochrane MS Group trials register (December 2004), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2004), MEDLINE (January 1966 to December 2004) and EMBASE (1974 to December 2004). We hand searched bibliographic references from retrieved studies and recent MS symposia reports, and contacted known studies' investigators.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included trials fulfilling all following criteria: randomised controlled trials (RCTs); adults with MS, out of exacerbation; AP or DAP treatment versus placebo; clinical endpoints. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Three reviewers independently extracted data and assessed trial quality from 17 full-paper studies. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Six studies (eight publications, 198 participants, all crossover trials) were considered. Five studies assessed the efficacy of AP versus placebo, one compared DAP with active placebo. Treatment duration ranged from hours to six months. Median quality score of the studies was three. </P>
<P>Of the 198 treated participants, there were six major side effects: one acute encephalopathy, three episodes of confusion, and two seizures. <BR/>Three studies (54 participants) assessed manual muscle testing, with 29 participants (54%) improving in at least one muscular district during study treatment versus four participants (7%) during placebo (odds ratio [OR] 14.5, 95% confidence interval [CI] 4.7 to 43.7). Nine out of 54 participants (17%) improved in ambulation during study treatment versus none during placebo (p &lt; 0.001). A lower Expanded Disability Status Scale (EDSS) score was found in 13/198 participants during study treatment (7%) versus none during placebo (p &lt; 0.001). No improvement in neuropsychological tests was found in three trials assessing cognitive function. Finally, 47/136 adults with MS (35%) felt better when receiving the study drug, against 7(5%) on placebo (OR 9.7, 95% CI 4.3 to 22.0). </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Currently available information allows no unbiased statement about safety or efficacy of aminopyridines for treating MS symptoms. Furthermore, we could not obtain any data on three unpublished RCTs (more than 300 participants). We conclude that publication bias remains a pervasive problem in this area, and that until the results of these unpublished studies are available to the scientific community, no confident estimate of effectiveness of aminopyridines in the management of MS symptoms is possible. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-11 11:08:46 +0200" MODIFIED_BY="Liliana Coco">
<BACKGROUND>
<P>Multiple sclerosis (MS) is the most important non-traumatic cause of neurological disability in young adults. Although MS etiology and pathogenesis remain imperfectly understood it is widely believed that the disease has an immune-mediated basis and occurs in genetically susceptible individuals. Inflammation and demyelination of the central nervous system are considered the main features of the disease (<LINK REF="REF-Prineas-1978" TYPE="REFERENCE">Prineas 1978</LINK>). More recently, substantial axonal damage has also been demonstrated by means of pathological and imaging studies (<LINK REF="REF-McDonald-1992" TYPE="REFERENCE">McDonald 1992</LINK>; <LINK REF="REF-Narayanan-1997" TYPE="REFERENCE">Narayanan 1997</LINK>; <LINK REF="REF-Trapp-1998" TYPE="REFERENCE">Trapp 1998</LINK>). <BR/>Despite advances in treatments that apparently have curative action, so far no intervention has proven effective in modifying long-term disease prognosis. Therefore symptomatic and supportive therapies remain important in the management of the various clinical manifestations of MS.<BR/>The potassium channel blockers 4-aminopyridine (AP) and 3,4-diaminopyridine (DAP) have been proposed as symptomatic therapies for MS; their mechanism of action is reviewed here reviewed briefly. During action potential propagation in a normal myelinated axon, sodium channels that are clustered in high density at the nodes of Ranvier open transiently, causing the action potential to jump from one node to the next (saltatory conduction). The internodal part of the axon is covered by myelin and contains fewer sodium channels but a higher density of potassium channels, which tend to oppose the generation of action potentials (<LINK REF="REF-Waxman-1996" TYPE="REFERENCE">Waxman 1996</LINK>). In demyelinated axons potassium channels appear on the axolemma and decrease action potential amplitude and duration. Potassium channel blockers increase action potential amplitude and duration thus improving nerve conduction in experimentally demyelinated animal nerves (<LINK REF="REF-Bostock-1978" TYPE="REFERENCE">Bostock 1978</LINK>; <LINK REF="REF-Sherrat-1980" TYPE="REFERENCE">Sherrat 1980</LINK>). An alternative mechanism of action has been recently proposed for AP; in experimentally demyelinated dorsal axons of rats the drug potentiates synaptic transmission and increases skeletal muscle twitch tension (<LINK REF="REF-Smith-2000" TYPE="REFERENCE">Smith 2000</LINK>). Over the last 10 years several RCT with AP and DAP in MS patients have been published, and the drugs have been proposed as effective symptomatic treatments, especially in temperature-sensitive patients (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Davis-1990" TYPE="STUDY">Davis 1990</LINK>; <LINK REF="STD-Stefoski-1991" TYPE="STUDY">Stefoski 1991</LINK>). DAP has also been proposed as a symptomatic treatment in patients with Lambert-Eaton myasthenic syndrome (<LINK REF="REF-McEvoy-1989" TYPE="REFERENCE">McEvoy 1989</LINK>). A number of side effects have also been reported, the most serious of which is the occurrence of seizures (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Polman-1994a" TYPE="STUDY">Polman 1994a</LINK>). Several approaches to minimizing aminopyridine toxicity have been proposed, such as finding a molecular analogue associated with fewer side effects and the best-tolerated formulation (i.e. sustained release preparations)(<LINK REF="STD-Bever-1995b" TYPE="STUDY">Bever 1995b</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>).<BR/>A previously published review on aminopyridines in MS did not follow the formal rules of systematic overview (<LINK REF="REF-Bever-1994a" TYPE="REFERENCE">Bever 1994a</LINK>); furthermore publication bias may limit interpretation of studies in this area: most RCTs have been relatively small, and a large completed <I>negative</I> study has not been published (<LINK REF="REF-Pogue-1998" TYPE="REFERENCE">Pogue 1998</LINK>). </P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the efficacy and safety of the aminopyridines AP and DAP in improving neurological deficits in MS patients. <BR/>The secondary objectives were subgroup analyses considering the molecule (AP or DAP), and type of preparation (regular or sustained release).</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-11 11:08:46 +0200" MODIFIED_BY="Liliana Coco">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>RCTs of AP or DAP versus placebo (either inert or active, e.g. nicotinic acid) were identified and considered for inclusion in the review. Truly randomised crossover studies were also included (i.e. crossover studies in which the sequence of treatment assignment was randomly allocated). Uncontrolled trials and controlled studies where the intervention was compared with other therapies were not included. Studies comparing DAP with AP were also excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Clinically definite (Poser or other internationally recognised classification criteria) MS patients aged 18 years or more of either sex. Patients in exacerbation were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Both AP and DAP versus placebo, given in any dose, route, or formulation (including sustained release) were considered. In studies where more than one dosage was compared to control treatment, all patients receiving the study intervention were aggregated, for the purposes of this review, into a single group. Subgroup analyses considering the molecule (AP or DAP), and type of preparation (regular or sustained release) were also considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The main events of interest were:<BR/>(1) Safety assessment: the number of dropouts and incidence of adverse events. Adverse events were categorised into (a) mild/moderate and (b) major events (death, seizures or any event requiring hospitalisation or medical treatment).<BR/>(2) Changes in disability or impairment scales assessing: (a) motor function, (b) visual acuity, (c) cognition, and (d) fatigue.<BR/>(3) Quality of life.<BR/>(4) Patients' subjective response.</P>
<P>Isolated neurophysiological improvement was not considered. <BR/>Outcomes were assessed overall, acutely (hours), and intermediately (at four weeks). The proportion of patients improved on the predefined outcome measures were also reported.<BR/>We sought to extract from each RCT the number of patients originally assigned to each treatment group so as to allow an intention-to-treat analysis, if the trial had not already been presented in this way.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-11 11:08:46 +0200" MODIFIED_BY="Liliana Coco">
<P>The databases were searched to locate publications written in English, French, German, Italian or Dutch.</P>
<ELECTRONIC_SEARCHES MODIFIED="2008-09-11 11:08:16 +0200" MODIFIED_BY="Liliana Coco">
<P>(1) Cochrane MS Group Trials Register (December 2004)<BR/>(2) Cochrane Central Register of Controlled Trials (CENTRAL) "The Cochrane Library Issue 4,2004"(<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)<BR/>(3) MEDLINE (from January 1966 to December 2004)(<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>)<BR/>(4) EMBASE (from 1974 to December 2004)(<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-11 11:08:25 +0200" MODIFIED_BY="Liliana Coco">
<P>(5) Reference lists of all available review articles and primary studies found by running the above mentioned databases.<BR/>(6) Handsearch of recent (1997 to 2002) symposia reports from the most important national neurological associations and MS societies in Europe and America.<BR/>(7) Contact with researchers participating in trials on aminopyridines.<BR/>(8) Inquiry to Elan/Acorda Pharmaceutical Research Corporation.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Study Selection</B>
<BR/>Three reviewers (AS, CT, BU) independently screened titles, abstracts, and descriptors of all studies identified by the search strategy and discarded irrelevant publications to create a list of eligible studies. After the potential trials and reviews had been retrieved, each reviewer independently applied the eligibility/exclusion criteria to unblinded full reports. </P>
<P>
<B>Data Extraction</B>
<BR/>The reviewer extracted from each study the following information, which was abstracted onto a predefined form: inclusion/exclusion criteria; number of participants excluded from the trial (not enrolled for logistical reasons, refused consent, not eligible); description of randomisation; description of the study and control treatment; description of blinding of treatment administration and of outcome assessment; definition of efficacy and safety endpoints; length of follow-up; number of participants withdrawn from or dropping out of the trial after randomisation; number of participants with incomplete follow-up; intention-to-treat analysis (whether performed or could be done); pre trial specification/justification of sample size; and testing for period and carry-over effects (cross-over studies only). Both interim analyses and final results were considered. There was no disagreement on study inclusion between authors. </P>
<P>
<B>Assessment of Study Quality</B>
<BR/>All three reviewers independently assessed the methodological quality of eligible trials published as full papers using the Jadad checklist (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The reviewers were not blinded to the names of the authors, institutions, journal, or study results. The Jadad scale consists of three items: description of randomisation, blinding, and attrition. The scale score ranges from zero (lowest possible score) to five (highest possible score), with two points given for description of randomisation and blinding, and one point given for description of attrition. Studies scoring less than three points are generally regarded as being of low methodological quality. For cross-over studies, we added an additional item assessing the washout period: one additional point was deducted from the global Jadad score if the washout period was not described, there was no washout period, or if the washout was described but considered inappropriate by the reviewer. <BR/>Inter-rater agreement on methodological quality scale scores was assessed by means of the kappa statistic. The kappa coefficient takes into account and corrects for chance-explained agreement; it ranges between zero (completely chance-explained agreement) and one (perfect agreement) (<LINK REF="REF-Fleiss-1971" TYPE="REFERENCE">Fleiss 1971</LINK>; <LINK REF="REF-Landis-1977" TYPE="REFERENCE">Landis 1977</LINK>). </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Electronic and manual searches identified 74 titles and abstracts. Of these, 47 were considered non pertinent. Of the remaining 27 references, one was a narrative overview (<LINK REF="REF-Bever-1994a" TYPE="REFERENCE">Bever 1994a</LINK>); three were dose-finding or tolerability studies (<LINK REF="STD-Bever-1990" TYPE="STUDY">Bever 1990</LINK>; <LINK REF="STD-Bever-1995a" TYPE="STUDY">Bever 1995a</LINK>; <LINK REF="STD-Bever-1995b" TYPE="STUDY">Bever 1995b</LINK>) and one was a duplicate publication (<LINK REF="STD-Bever-1995b" TYPE="STUDY">Bever 1995b</LINK>). Five studies were case series (<LINK REF="STD-Bertelsmann-1992" TYPE="STUDY">Bertelsmann 1992</LINK>; <LINK REF="STD-Polman-1994a" TYPE="STUDY">Polman 1994a</LINK>; <LINK REF="STD-Fujihara-1998" TYPE="STUDY">Fujihara 1998</LINK>; <LINK REF="STD-Landete-1998" TYPE="STUDY">Landete 1998</LINK>; <LINK REF="STD-Sheean-1998" TYPE="STUDY">Sheean 1998</LINK>); four were non randomised studies (<LINK REF="STD-Jones-1983" TYPE="STUDY">Jones 1983</LINK>; <LINK REF="STD-Stefoski-1987" TYPE="STUDY">Stefoski 1987</LINK>; <LINK REF="STD-Davis-1990" TYPE="STUDY">Davis 1990</LINK>; <LINK REF="STD-Stefoski-1991" TYPE="STUDY">Stefoski 1991</LINK>); and 13 were RCTs. Five references were excluded since they were duplicate studies (<LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>; <LINK REF="STD-de-Waal-1994" TYPE="STUDY">de Waal 1994</LINK>; <LINK REF="STD-Smits-1994b" TYPE="STUDY">Smits 1994b</LINK>; <LINK REF="STD-Rossini-1996a" TYPE="STUDY">Rossini 1996a</LINK>; <LINK REF="STD-Rossini-1996b" TYPE="STUDY">Rossini 1996b</LINK>), one was an AP versus DAP comparative trial (<LINK REF="STD-Polman-1994b" TYPE="STUDY">Polman 1994b</LINK>), and one was excluded since only paraclinical endpoints were considered (<LINK REF="STD-van-Diemen-1993b" TYPE="STUDY">van Diemen 1993b</LINK>), in the same participants to a previously published study (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>). Of the remaining seven trials, one was an abstract and no detailed results have been published over the 12 years (<LINK REF="STD-Carter-1993" TYPE="STUDY">Carter 1993</LINK>), and six were full-text articles (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>). One paper of Van Diemen (<LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>) was in two parts, one being a duplicate (part II) and the other evaluating eye movements in the same patients reported in a previous publication (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>). Consequently this publication is considered both among included (part I) and excluded studies (part II). In the table of excluded studies however we could not report <LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>, part II, since a single reference can not be reported two times, i.e. among both included and excluded studies. The reader should consider this point when examining the table and the reference of excluded studies, which should include also <LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>, part II. All eligible RCTs had a crossover design; in no instance was information on the individual study period given. <BR/>Three unpublished trials were also identified by contact with trialists and by searching the National MS Society publication of clinical trials of new agents in MS. <BR/>In spring 1999 we contacted the principal investigators of all the included RCTs, and principal investigators/pharmaceutical company sponsor of unpublished studies. For the published trials, an extraction form was also enclosed. Four to six months, and also one year later, each investigator was contacted again. We have so far received answers from the authors of four studies, expressing their willingness to give the information requested (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>; <LINK REF="STD-Polman-1994b" TYPE="STUDY">Polman 1994b</LINK>; <LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>). <I>Elan/Acorda</I> also answered our second request, stating: "Our policy is not to release specific data pertaining to our clinical trials prior to their publication". </P>
<P>This review is based on a total of six studies (seven publications) that were randomised, placebo-controlled, double-blind trials. There is one more abstract awaiting assessment.<BR/>All studies were single centre crossover trials. Five studies assessed the efficacy of AP versus placebo. The daily dose of AP ranged from up to 40 mg (<LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>)] to up to 100 mg (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>). One study was a double cross-over comparing placebo with low dose and high dose AP (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>). One study assessed the efficacy of DAP versus nicotinic acid (active placebo) (<LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>). Duration of treatment ranged from hours (<LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>; <LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>) to six months (<LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>). Safety was assessed in all studies from clinical side effects, and by means of routine laboratory testing (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>), ECG (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>) and EEG changes (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>).</P>
<P>All six studies assessed several efficacy outcomes. These included overall measures of impairment and disability (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>; <LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>)], quantitative motor testing (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>), fatigue (<LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>), visual testing (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>) eye movement registration (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK> ), neuropsychological testing (<LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>), neurophysiological testing (<LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>), fatigue (<LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>), and patients' subjective impressions (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>). Primary study endpoints were specified a priori in four trials (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>). </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Three observers (AS, CT, BU) independently assessed the quality of the included trials. The inter-rater agreement on 16 full paper articles was almost perfect for items assessing whether the study was randomised, whether it was double blind, and on the appropriateness of the washout period (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Moderate agreement was found for appropriateness of the randomisation method, and for withdrawal/dropout reporting. The kappa value for the appropriateness of double blinding was close to zero. This finding is the result of imbalance in marginal totals distribution in the concordance table, and has been described in the literature (<LINK REF="REF-Feinstein-1990" TYPE="REFERENCE">Feinstein 1990</LINK>). To overcome this problem, the proportion of agreement in the raters' positive and negative judgments is also reported in the table, and indicated as P(pos) and P(neg). </P>
<P>The median quality score of the seven included publications (six studies) was three (range two to five). The randomisation method was reported in only one study (<LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>). All the studies were double blind, and the blinding was described in all of them. Withdrawals and dropouts were described in five publications (<LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>; <LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>). Washout was described and considered appropriate in two papers (<LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>). One study had no washout period (<LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>At this point therefore, this review is based on six RCTs (198 participants) reported in seven full-paper articles. All the included studies were single institution, double blind, crossover RCTs. Three were from the US, two from the Netherlands and one was an Italian study. Because of lack of information on the individual periods of the studies, we could not enter the data into MetaView. It was in fact possible to perform only a limited number of comparisons of categorical outcomes, and for all these comparisons, events were reported for aggregated periods only (i.e. treatment or placebo phases). In no instance was information given on the number of participants achieving a specific outcome in a specific phase. No trial was excluded on the basis of quality score. A short summary of the main findings of the six studies is reported in table form. The following data were also calculated on the basis of information given in the original published papers: </P>
<P>
<B>Safety</B>
<BR/>Among the 198 treated patients, six major side effects were reported: one acute encephalopathy (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>), three episodes of confusion (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>), and two seizures (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>). Four major side effects were reported in 36 people with MS during treatment with DAP (11%) (<LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>), and two during AP treatment (1%). Both epileptic fits were tonic-clonic seizures in persons with no history of epilepsy or loss of consciousness. One episode was reported on DAP treatment, and the other during AP treatment, when serum AP packed at 104 ng/ml. Withdrawals and dropouts were reported in all six studies, with 18 attritions in 162 participants treated with AP (11%) (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>), and eight attritions in 36 participants treated with DAP (22%) (<LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>). No participant was lost to follow up. Finally, in 46% (32 participants) of a group of participants treated with intravenous AP, side effects were considered the reason to stop the infusion (<LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>).</P>
<P>
<B>Motor function</B>
<BR/>Three RCTs (54 participants) considered motor function testing as study outcome (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>). Manual muscle testing was performed in all the studies considered, with 29 participants (54%) improving in at least one district during study treatment versus four participants (7%) during placebo (odds ratio [OR] 14.5, 95% confidence interval [CI] 4.75 to 43.72, p &lt; 0.001). </P>
<P>
<B>Eye movements</B>
<BR/>Two trials assessed eye movement by means of smooth pursuit gain recordings (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>). The two studies evaluated this parameter in 70 participants after intravenous infusion of AP (<LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>), and also over a three-month oral administration period (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-van-Diemen-1993a" TYPE="STUDY">van Diemen 1993a</LINK>). The authors found mean improvements in smooth pursuit gain in both eyes during both acute and prolonged treatment with AP (data not shown). </P>
<P>
<B>Ambulation</B>
<BR/>Three studies (54 patients) assessed the efficacy of aminopyridines on ambulation, which was assessed with the Ambulation Index (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>) or with timed gait (patients were judged as improved if timed gait decreased by 10 seconds or more) (<LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>). Overall, nine participants (17%) improved in ambulation during study treatment versus none during placebo (p &lt; 0.0001). <BR/>
<B>
<BR/>EDSS<BR/>
</B>All six RCTs considered Expanded Disability Status Scale (EDSS) as study outcome. An improvement in EDSS score was found in 13 participants during study treatment (7%) versus none during placebo (p &lt; 0.0001). <BR/>
<BR/>
<B>Visual function</B>
<BR/>Three trials assessed visual function by means of mean changes in contrast sensitivity, flicker fusion frequency, and evoked potential latencies (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>).Two studies also considered evoked potential amplitudes (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>). Significant changes in favour of treatment were reported for evoked potential latency in one study (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>), and for contrast sensitivity in another (<LINK REF="STD-Bever-1994b" TYPE="STUDY">Bever 1994b</LINK>). <BR/>
<BR/>
<B>Cognitive function</B>
<BR/>No improvement in neuropsychological tests was detected in three trials that evaluated cognitive function changes. Two studies employed the Brief Repeatable Battery of Neuropsychological Tests as outcome measure (<LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>), and the Italian trial used an ad hoc neuropsychological battery consisting in the following tests: Auditory Attention Test, Forward Digit and Corsi's Block Span test, 15' Delayed Recall of the Rey's 15-Words List, Rey's Figure A, Phonological Word Fluency, Benton's Line Orientation Test, Token Test, Wisconsin Card Sorting Test, and Raven's Progressive Matrices (<LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>). In two trials the intervention drug was oral AP (<LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>; <LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>), and in one it was sustained-release DAP (<LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>).</P>
<P>
<B>Fatigue</B>
<BR/>The Fatigue Severity Scale (FSS) was the prespecified primary endpoint of one study (<LINK REF="STD-Rossini-2001" TYPE="STUDY">Rossini 2001</LINK>). Mean changes in the FSS did not differ between placebo and AP treatment. Investigators found a significant difference in favour of AP in participants with AP blood level &gt; 30 ng/ml (Tukey's adjusted ANOVA, p = 0.05). It should be noted that the cut off point was selected post hoc, and the number of participants with high values (out of 31 participants in whom AP serum level was determined) was not reported. </P>
<P>
<B>Patients' subjective response </B>
<BR/>Patients' subjective impression was assessed in four studies (136 participants) (<LINK REF="STD-van-Diemen-1992" TYPE="STUDY">van Diemen 1992</LINK>; <LINK REF="STD-Smits-1994a" TYPE="STUDY">Smits 1994a</LINK>; <LINK REF="STD-Bever-1996" TYPE="STUDY">Bever 1996</LINK>; <LINK REF="STD-Schwid-1997" TYPE="STUDY">Schwid 1997</LINK>). Overall, 47 participants (35%) felt improved when receiving the study drug, and seven participants (5%) felt improved on placebo (OR 9.73, 95% CI 4.28 to 22.05, p &lt; 0.0001). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Our purpose was to conduct a systematic review of the safety and efficacy of aminopyridines in the management of symptoms of MS. Aminopyridines are only available as preparations specifically made up by the dispensing pharmacist. To improve tolerability and minimise side effects, <I>Elan/Acorda</I> devised an oral slow-release AP formulation and sponsored a multicenter RCT. The trial has not been published so far, and the slow-release AP formulation has not been registered. </P>
<P>We considered only RCTs, and all were crossover studies. Regarding safety, there were six major side effects in a total of 198 treated people with MS. This 3% frequency of serious adverse events is not negligible, especially if we consider that all the studies included narrowly defined participants (i.e., all the trials excluded people with a history of seizures, unexplained loss of consciousness, or epileptiform activity on EEG). </P>
<P>With regard to efficacy outcomes, since the aminopyridines are used to treat many symptoms of MS, the number of outcome considered in the studies and within a single study was high. Since few common end points were available across trials and because of lack of information on individual periods within all of the studies, none of the data could be pooled for quantitative analyses. Similarly, we could not perform any subgroup analyses considering a specific drug (AP or DAP), dosage, or formulation (regular or sustained release). Publication bias was another, and possibly more important concern. We traced three unpublished RCTs involving a planned number of 331 people with MS. It is unlikely that, irrespective of study results, any indexed journal would refuse to publish such recently performed trials that in at least two instances were well powered, multicenter trials. We therefore feel that the currently available evidence on the efficacy of AP and DAP for treating symptoms of people with MS is biased. </P>
<P>Publication bias is therefore the major concern of this systematic review. To note that one RCT published as an abstract has been considered among excluded studies in the most recent update since full data have not been availbe over a 12 year period (<LINK REF="STD-Carter-1993" TYPE="STUDY">Carter 1993</LINK>). Other negative aspects are the following: <BR/>(1) The benefit of aminopyridines may be overestimated in this review since in all but two trials the primary endpoint was not specified, and in such a many-outcome situation, this raises the distinct possibility of false positive findings. <BR/>(2) Furthermore, the published studies tended to include detailed data only on outcomes found to be statistically significant. <BR/>(3) When dealing with a symptomatic intervention outcomes which are meaningful to patients should be used. In no instance was quality of life considered as a study outcome, although patients' subjective response was assessed in four trials. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This review cannot provide a reliable statement concerning the efficacy of AP or DAP for treating symptoms of people with MS. A conclusion on the safety of these preparations is even more problematic due to the limited power of the current systematic review to reliably detect major adverse events, and to the low external validity of the results (narrow entry criteria). </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a clear need to make available to the scientific community the results of unpublished trials on safety and efficacy of the aminopyridines in people with MS. We do not therefore conclude that more trials are needed in this area, but that these studies should be published.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors wish to acknowledge the assistance of the Cochrane Multiple Sclerosis Review Group in the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The reviewers have no known conflicts of interest. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>All reviewers contributed to the design of the protocol and writing of the review.<BR/>Assessment of studies and data extration was carried out by three reviewers (AS, CT, BU).</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-11 11:12:59 +0200" MODIFIED_BY="Liliana Coco">
<STUDIES MODIFIED="2008-08-21 12:00:58 +0200" MODIFIED_BY="Deirdre Beecher">
<INCLUDED_STUDIES MODIFIED="2008-08-21 11:57:03 +0200" MODIFIED_BY="Deirdre Beecher">
<STUDY DATA_SOURCE="PUB" ID="STD-Bever-1994b" NAME="Bever 1994b" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bever CT, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, et al</AU>
<TI>The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>6</NO>
<PG>1054-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bever-1996" NAME="Bever 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bever CT, Anderson PA, Leslie J, Panitch HS, Dhib-Jalbut S, Khan OA, et al</AU>
<TI>Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>6</NO>
<PG>1457-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossini-2001" NAME="Rossini 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, et al</AU>
<TI>Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine</TI>
<SO>Multiple Sclerosis</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>6</NO>
<PG>354-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwid-1997" NAME="Schwid 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD</AU>
<TI>Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48</VL>
<NO>4</NO>
<PG>817-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smits-1994a" NAME="Smits 1994a" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smits RCF, Emmen HH, Bertlesmann FW, Kulig BM, van Loenen AC, Polman CH</AU>
<TI>The effects of 4-Aminopyridine on cognitive function in patients with multiple sclerosis: A pilot study</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>9</NO>
<PG>1701-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Diemen-1992" MODIFIED="2008-08-21 11:57:03 +0200" MODIFIED_BY="Deirdre Beecher" NAME="van Diemen 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-08-21 11:57:03 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Diemen HAM, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, et al</AU>
<TI>The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, cross-over study</TI>
<SO>Annals of Neurology</SO>
<YR>1992</YR>
<VL>32</VL>
<NO>2</NO>
<PG>123-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Diemen-1993a" NAME="van Diemen 1993a" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Diemen HAM, Polman CH, Koetsier JC, van Loenen AC, Nauta JJ, Bertelsmann FW</AU>
<TI>4-Aminopyridine in patients with multiple sclerosis: Dosage and serum level related to efficacy and safety</TI>
<SO>Clinical Neuropharmacolgy</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>3</NO>
<PG>195-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-08-21 12:00:58 +0200" MODIFIED_BY="Deirdre Beecher">
<STUDY DATA_SOURCE="PUB" ID="STD-Bertelsmann-1992" NAME="Bertelsmann 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertelsmann FW, Polman CH, van Diemewn HAM, de Waal R, Koetsier JC</AU>
<TI>Comparison between 4-aminopyridine and 3,4 diaminopyridine in the treatment of multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1992</YR>
<VL>32</VL>
<NO>2</NO>
<PG>256</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bever-1990" NAME="Bever 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bever CT, Leslie J, Camenga DL, Panitch HS, Johnson KB</AU>
<TI>Preliminary trial of 3,4 diaminopyridine in patients with multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1990</YR>
<VL>27</VL>
<PG>421-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bever-1995a" MODIFIED="2008-08-21 11:58:28 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Bever 1995a" YEAR="1995">
<REFERENCE MODIFIED="2008-08-21 11:58:28 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bever CT, Young D, Tierney D, Conway K, Kats E, Costello K, et al</AU>
<TI>The pharmacokinetics and tolerability of a slow-release formulation of 4-aminopyridine in multiple sclerosis patients</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45 Suppl 4</VL>
<PG>A351</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bever-1995b" NAME="Bever 1995b" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bever C, Katz E, Tierney D, Johnson K</AU>
<TI>Experience with slow release 4-aminopyridine in multiple sclerosis patients: long term tolerability and safety</TI>
<SO>Journal of Neuroimmunology</SO>
<YR>1995</YR>
<VL>1 Suppl</VL>
<PG>58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1993" MODIFIED="2008-08-21 11:58:53 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Carter 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-08-21 11:58:53 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter JL, Stevens JC, Smith B, Caselli RJ, Metcalf A, Windebank A, et al</AU>
<TI>A double-blind, placebo-controlled crossover trial of 3,4 diaminopyridine in the symptomatic treatment of multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>2</NO>
<PG>272-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1990" NAME="Davis 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis FA, Stefoski D, Rush J</AU>
<TI>Orally admimistered 4-aminopyridine improves clinical signs in multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1990</YR>
<VL>27</VL>
<PG>186-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Waal-1994" NAME="de Waal 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Waal R, Polman CH, Bertlesmann FW, van Diemen HAM, Koetsier JC</AU>
<TI>The treatment of multiple sclerosis(MS): 4-aminopyridine (4-AP)</TI>
<SO>Journal of Neurology</SO>
<YR>1994</YR>
<VL>241</VL>
<PG>S102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujihara-1998" NAME="Fujihara 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujihara K, Miyoshi T</AU>
<TI>The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1998</YR>
<VL>159</VL>
<PG>102-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1983" NAME="Jones 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ</AU>
<TI>Effects of 4-aminopyridine in patients with multiple sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1983</YR>
<VL>60</VL>
<PG>353-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landete-1998" NAME="Landete 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landete L, Casanova B, Coret F, Millet E, Vitchez JJ</AU>
<TI>Low dosis of 4-Aminopyridine in the treatment of multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>1998</YR>
<VL>4</VL>
<PG>386</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polman-1994a" NAME="Polman 1994a" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polman CH, Bertelesmann FW, de Waal R, van Diemen HAM, Uitdehaag BMJ, van Loenen AC, et al</AU>
<TI>4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1994</YR>
<VL>51</VL>
<PG>1136-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polman-1994b" NAME="Polman 1994b" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polman CH, Bertlesmann FW, de Waal R, van Diemen HAM, Uitdehaag BMJ, van Loenen AC, et al</AU>
<TI>4-Aminopyridine is superior to 3,4 diaminopyridine in the treatment of patients with multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1994</YR>
<VL>51</VL>
<PG>1136-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossini-1996a" MODIFIED="2008-08-21 12:00:02 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Rossini 1996a" YEAR="1996">
<REFERENCE MODIFIED="2008-08-21 12:00:02 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossini PM, Arduini A, Carlesimo GA, Gracieffa A, Grasso MG, Lupoi D, et al</AU>
<TI>4-Aminopyridine treatment in chronic progressive multiple sclerosis: a 6 month double-blind placebo-controlled, crossover study</TI>
<SO>European Journal of Neurology</SO>
<YR>1996</YR>
<VL>3 Suppl 4</VL>
<PG>29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossini-1996b" MODIFIED="2008-08-21 12:00:24 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Rossini 1996b" YEAR="1996">
<REFERENCE MODIFIED="2008-08-21 12:00:24 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossini PM, Arduini A, Carlesimo GA, Gracieffa A, Grasso MG, Lupoi D, et al</AU>
<TI>4-Aminopyridine treatment in chronic progressive multiple sclerosis: a 6-month double-blind placebo-controlled, cross-over study by AMIT (Aminopyridine Italian Study)</TI>
<SO>European Journal of Neurology</SO>
<YR>1996</YR>
<VL>3 Suppl 5</VL>
<PG>91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheean-1998" MODIFIED="2008-08-21 12:00:38 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Sheean 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-08-21 12:00:38 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheean GL, Murray NMF, Rothwell JC, Miller DH, Thompson AJ</AU>
<TI>An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis</TI>
<SO>Brain</SO>
<YR>1998</YR>
<VL>121</VL>
<PG>967-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smits-1994b" MODIFIED="2008-08-21 12:00:58 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Smits 1994b" YEAR="1994">
<REFERENCE MODIFIED="2008-08-21 12:00:58 +0200" MODIFIED_BY="Deirdre Beecher" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Smits RCF, Emmen HH, Bertlesmann FW, Kulig BM, van Loenen AC, Polman CH, et al</AU>
<TI>The effects of 4-Aminopyridine on cognitive function in patients with multiple sclerosis: A pilot study</TI>
<SO>Journal of Neurology</SO>
<YR>1994</YR>
<VL>241</VL>
<PG>S102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stefoski-1987" NAME="Stefoski 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stefoski D, Davis FA, Faut M, Schauf CL</AU>
<TI>4-Aminopyridine improves clinical signs in multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1987</YR>
<VL>21</VL>
<NO>1</NO>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stefoski-1991" NAME="Stefoski 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW</AU>
<TI>4-Aminopyridine in multiple sclerosis: Prolonged administration</TI>
<SO>Neurology</SO>
<YR>1991</YR>
<VL>41</VL>
<NO>9</NO>
<PG>1344-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Diemen-1993b" NAME="van Diemen 1993b" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Diemen HAM, Polman CH, van Dongen MM, Nauta JJ, Strijers RL, van Loenen AC, et al</AU>
<TI>4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neuropsychological study</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1993</YR>
<VL>116</VL>
<NO>2</NO>
<PG>220-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-11 11:12:59 +0200" MODIFIED_BY="Liliana Coco">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-11 11:12:59 +0200" MODIFIED_BY="Liliana Coco">
<REFERENCE ID="REF-Bever-1994a" MODIFIED="2008-09-11 11:12:35 +0200" MODIFIED_BY="Liliana Coco" NAME="Bever 1994a" TYPE="JOURNAL_ARTICLE">
<AU>Bever CT jr</AU>
<TI>The current status of studies of aminopyridines in patients with multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1994</YR>
<VL>36 Suppl</VL>
<PG>118-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bostock-1978" MODIFIED="2008-09-11 11:12:59 +0200" MODIFIED_BY="Liliana Coco" NAME="Bostock 1978" TYPE="JOURNAL_ARTICLE">
<AU>Bostock H, Sherrat RM, Sears TA</AU>
<TI>Overcoming conduction failure in demyelinated nerve by prolonging action potentials</TI>
<SO>Nature</SO>
<YR>1978</YR>
<VL>274</VL>
<PG>385-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feinstein-1990" NAME="Feinstein 1990" TYPE="JOURNAL_ARTICLE">
<AU>Feinstein AR, Cicchetti DV</AU>
<TI>High agreement but low kappa: I. The problems of two paradoxes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1990</YR>
<VL>43</VL>
<NO>6</NO>
<PG>543-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleiss-1971" NAME="Fleiss 1971" TYPE="JOURNAL_ARTICLE">
<AU>Fleiss JH</AU>
<TI>Measuring nominal scale agreement among many raters</TI>
<SO>Psychological Bulletin</SO>
<YR>1971</YR>
<VL>76</VL>
<PG>378-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore RA, Carroll D, Jenkinson C, Reynolds DJL, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of report of randomised clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landis-1977" NAME="Landis 1977" TYPE="JOURNAL_ARTICLE">
<AU>Landis JR, Koch GG</AU>
<TI>The measurement of observer agreement for categorical data</TI>
<SO>Biometrics</SO>
<YR>1977</YR>
<VL>33</VL>
<PG>159-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-1992" MODIFIED="2008-08-21 10:31:44 +0200" MODIFIED_BY="Liliana Coco" NAME="McDonald 1992" TYPE="JOURNAL_ARTICLE">
<AU>McDonald WI, Miller DH, Barnes D</AU>
<TI>The pathological evolution of multiple sclerosis</TI>
<SO>Neuropathology &amp; Applied Neurobiology</SO>
<YR>1992</YR>
<VL>18</VL>
<NO>4</NO>
<PG>319-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McEvoy-1989" MODIFIED="2008-08-21 10:31:51 +0200" MODIFIED_BY="Liliana Coco" NAME="McEvoy 1989" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy KM, Windebank AJ, Daube JR, et al</AU>
<TI>3,4 Diamynopiridine in the treatment of Lambert-Eaton myastenic syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>321</VL>
<PG>1567-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Narayanan-1997" MODIFIED="2008-08-21 10:32:06 +0200" MODIFIED_BY="Liliana Coco" NAME="Narayanan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Narayanan S, Fu L, Pioro E, De Stefano N, Collins DL, Francis GS, et al</AU>
<TI>Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions</TI>
<SO>Annals of Neurology</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>3</NO>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pogue-1998" MODIFIED="2008-08-21 10:32:21 +0200" MODIFIED_BY="Liliana Coco" NAME="Pogue 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pogue J, Yusuf S</AU>
<TI>Overcoming the limitations of current meta-analysis of randomised controlled trials</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<NO>9095</NO>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prineas-1978" MODIFIED="2008-08-21 12:04:01 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Prineas 1978" TYPE="JOURNAL_ARTICLE">
<AU>Prineas JW, Connell F</AU>
<TI>The fine structure of chronically active multiple sclerosis plaques</TI>
<SO>Neurology</SO>
<YR>1978</YR>
<VL>28</VL>
<NO>9 pt 2</NO>
<PG>68-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherrat-1980" MODIFIED="2008-08-21 10:32:39 +0200" MODIFIED_BY="Liliana Coco" NAME="Sherrat 1980" TYPE="JOURNAL_ARTICLE">
<AU>Sherrat RM, Bostock H, Sears TA</AU>
<TI>Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibers</TI>
<SO>Nature</SO>
<YR>1980</YR>
<VL>283</VL>
<PG>570-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2000" NAME="Smith 2000" TYPE="JOURNAL_ARTICLE">
<AU>Smith KJ, Felts PA, John GR</AU>
<TI>Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension</TI>
<SO>Brain</SO>
<YR>2000</YR>
<VL>123</VL>
<PG>171-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trapp-1998" MODIFIED="2008-08-21 10:33:11 +0200" MODIFIED_BY="Liliana Coco" NAME="Trapp 1998" TYPE="JOURNAL_ARTICLE">
<AU>Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L</AU>
<TI>Axonal transection in the lesions of multiple sclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>5</NO>
<PG>278-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waxman-1996" MODIFIED="2008-08-21 12:05:45 +0200" MODIFIED_BY="Deirdre Beecher" NAME="Waxman 1996" TYPE="BOOK_SECTION">
<AU>Waxman SG</AU>
<TI>Patophysiology of demyelinated and remyelinated axons</TI>
<SO>Handbook of multiple sclerosis</SO>
<YR>1996</YR>
<PG>257-94</PG>
<EN>2nd</EN>
<ED>Cook SD</ED>
<PB>Marcel Dekker</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bever-1994b">
<CHAR_METHODS>
<P>Design: RCT, crossover double-blind<BR/>Quality score: 2 (1/2/0/-1)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Participants: 8 people with MS, temperature-sensitive, EDSS 3.0-8.0, with visual and lower extremity motor deficits</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Placebo, or AP 30-59 ng/ml/day PO, or AP 10-100 ng/ml/day PO</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EFFICACY:<BR/>EDSS;<BR/>AI;<BR/>Strength score;<BR/>Videotape score;<BR/>Quantitative motor testing (hamstring, quadriceps);<BR/>Visual testing (contrast sensitivity, flicker fusion frequency, P100 latency).<BR/>SAFETY/TOLER.:<BR/>Clinical side effects;<BR/>ECG;<BR/>EEG;<BR/>Routine blood examination;<BR/>Serum AP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Observation period: 30 hours.</P>
<P>We are attempting to contact the authors for information on each study period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bever-1996">
<CHAR_METHODS>
<P>Design: RCT, crossover double-blind<BR/>Quality score: 4 (1/2/1/0)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Participants: 36 people with MS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Active placebo (nicotinic acid), or DAP up to 100 mg/day PO</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EFFICACY:<BR/>EDSS;<BR/>AI;<BR/>Strength score;<BR/>Videotape score;<BR/>Quantitative motor testing (hamstring, quadriceps);<BR/>Manual motor test score;<BR/>BRBNT; <BR/>Patient's subjective impression.<BR/>SAFETY/TOLER:<BR/>Clinical side effects;<BR/>Serum DAP level</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Observation period: one month</P>
<P>We are attempting to contact the authors for information on each study period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rossini-2001">
<CHAR_METHODS>
<P>Design: RCT, crossover double-blind<BR/>Quality score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Participants: 54 people with MS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Placebo, or AP 32 mg/day PO</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EFFICACY:<BR/>Fatigue Severity Scale; EDSS;<BR/>neuropsychological battery (9 tests);<BR/>neurophysiological evaluation (VEPs, SEPs, MEPs)<BR/>SAFETY/TOLER:<BR/>Clinical side effects; ECG; biological parameters; Hamilton's Depression Scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Observation period: 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schwid-1997">
<CHAR_METHODS>
<P>Design: RCT, crossover double-blind<BR/>Quality score: 5 (2/2/1/0)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Participants: 10 people with MS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Placebo, or AP sustained-release 35 mg/day PO</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EFFICACY:<BR/>EDSS;<BR/>Timed gait;<BR/>Maximum voluntary isometric contraction testing;<BR/>Composite manual muscle testing; <BR/>Grip strength;<BR/>Patient's global impression.<BR/>SAFETY/TOLER:<BR/>Clinical side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Observation period: one week</P>
<P>We are attempting to contact the authors for information on each study period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smits-1994a">
<CHAR_METHODS>
<P>Design: RCT, crossover double-blind</P>
<P>Quality score: 2 (1/2/0/-1)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: The Netherlands<BR/>Participants: 20 people with MS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Placebo, or AP 20-40 mg/day PO</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EFFICACY:<BR/>EDSS;<BR/>BRBNT;<BR/>Patients' subjective impression.<BR/>SAFETY/TOLER:<BR/>Clinical side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Observation period: 2 weeks</P>
<P>We are attempting to contact the authors for information on each study period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-Diemen-1992">
<CHAR_METHODS>
<P>Design: RCT, double crossover double-blind<BR/>Quality score: 3 (1/2/1/-1)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: The Netherlands<BR/>Participants: 70 people with MS , EDSS 2.0-7.5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Placebo, or AP up to 0.5 mg/kg/day PO</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EFFICACY:<BR/>EDSS;<BR/>FS;<BR/>No. of relapses;<BR/>Visual testing (contrast sensitivity, visual acuity, visual evoked potentials latency and amplitude);<BR/>Eye movement registration (smooth pursuit gain, saccadic latencies and peak velocities);<BR/>Patients' subjective impression.<BR/>SAFETY/TOLER:<BR/>Clinical side effects;<BR/>Routine blood examination;<BR/>EEG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Observation period: 3 months</P>
<P>We are attempting to contact the authors for information on each study period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-Diemen-1993a">
<CHAR_METHODS>
<P>Design: RCT, double crossover double-blind<BR/>Quality score: 3 (1/2/1/-1)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: The Netherlands<BR/>Participants: 70 people with MS, EDSS 2.0-7.5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Placebo, or AP up to 0.5 mg/kg/day IV drip (60 to 260 min.)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EFFICACY:<BR/>Eye movement registration (smooth pursuit gain).<BR/>SAFETY/TOLER:<BR/>Clinical side effects;<BR/>4-Aminopyridine serum level;<BR/>ECG.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Phase I study only </P>
<P>Observation period: mean 120 min after ending infusion.</P>
<P>We are attempting to contact the authors for information on each study period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AI: Ambulation Index <BR/>BRBNT: Brief repeatable battery of neuropsychological tests (selective reminding, 10/36 spatial recall - long term storage, symbol digit modalities, paced auditory serial addition, word list generation) <BR/>EDSS: Expanded Disability Status Scale <BR/>ECG: electrocardiogram <BR/>EEG: electroencephalogram <BR/>FS: Kurtzke's Functional Systems <BR/>MEPs: Motor evoked potentials<BR/>MS: multiple sclerosis<BR/>PO: per os<BR/>SEPs: sensory evoked potentials<BR/>VEPs: Visual evoked potentials <BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bertelsmann-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bever-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Dose finding/tolerability</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bever-1995a">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Dose finding/tolerability</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bever-1995b">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Duplicate of Bever 1995a</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carter-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>No detailed data published nor provided by authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davis-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Non randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Waal-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate of Polman 1994b<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fujihara-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Non randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Landete-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Polman-1994a">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Polman-1994b">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Comparative trial (AP versus DAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rossini-1996a">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Duplicate of Rossini 2001</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rossini-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Duplicate of Rossini 2001</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sheean-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smits-1994b">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Duplicate study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stefoski-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Non randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stefoski-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Non randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Diemen-1993b">
<CHAR_REASON_FOR_EXCLUSION>
<P>
<BR/>Only paraclinical end points, same patients as in van Diemen 1992</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bever-1994b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bever-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rossini-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schwid-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Smits-1994a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-van-Diemen-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-van-Diemen-1993a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-09-11 11:10:34 +0200" MODIFIED_BY="Liliana Coco">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-09-11 11:10:34 +0200" MODIFIED_BY="Liliana Coco" NO="1">
<TITLE MODIFIED="2008-09-11 11:10:34 +0200" MODIFIED_BY="Liliana Coco">Interrater agreement on 17 studies published as full papers</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>P(pos)</P>
</TH>
<TH>
<P>P(neg)</P>
</TH>
<TH>
<P>Kappa</P>
</TH>
<TH>
<P>p value</P>
</TH>
</TR>
<TR>
<TD>
<P>Randomised study</P>
</TD>
<TD>
<P>0.56</P>
</TD>
<TD>
<P>0.42</P>
</TD>
<TD>
<P>1.00</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Randomisation appropriateness</P>
</TD>
<TD>
<P>0.18</P>
</TD>
<TD>
<P>0.76</P>
</TD>
<TD>
<P>0.69</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Double blind study</P>
</TD>
<TD>
<P>0.54</P>
</TD>
<TD>
<P>0.44</P>
</TD>
<TD>
<P>1.00</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Double blinding appropriateness</P>
</TD>
<TD>
<P>0.93</P>
</TD>
<TD>
<P>0.04</P>
</TD>
<TD>
<P>-0.06</P>
</TD>
<TD>
<P>0.61</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawals/dropouts</P>
</TD>
<TD>
<P>0.56</P>
</TD>
<TD>
<P>0.40</P>
</TD>
<TD>
<P>0.70</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Washout</P>
</TD>
<TD>
<P>0.62</P>
</TD>
<TD>
<P>0.34</P>
</TD>
<TD>
<P>0.86</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-08-21 12:11:39 +0200" MODIFIED_BY="Deirdre Beecher">
<APPENDIX ID="APP-01" MODIFIED="2008-08-21 12:09:25 +0200" MODIFIED_BY="Deirdre Beecher" NO="1">
<TITLE MODIFIED="2008-08-21 12:07:40 +0200" MODIFIED_BY="Deirdre Beecher">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-21 12:09:25 +0200" MODIFIED_BY="Deirdre Beecher">
<P>#1        "multiple sclerosis"</P>
<P>#2        MeSH descriptor Multiple Sclerosis explode all trees</P>
<P>#3        "Demyelinating disease*"</P>
<P>#4        MeSH descriptor Demyelinating Diseases, this term only</P>
<P>#5        "transverse myelitis"</P>
<P>#6        MeSH descriptor Myelitis, Transverse, this term only</P>
<P>#7        "neuromyelitis optica"</P>
<P>#8        "optic neuritis"</P>
<P>#9        MeSH descriptor Optic Neuritis explode all trees</P>
<P>#10      "encephalomyelitis acute disseminated"</P>
<P>#11      MeSH descriptor Encephalomyelitis, Acute Disseminated, this term only</P>
<P>#12      "devic"</P>
<P>#13      aminopyridine*</P>
<P>#14      MeSH descriptor Aminopyridines explode all trees</P>
<P>#15      dap</P>
<P>#16      diaminopyridine</P>
<P>#17      MeSH descriptor Potassium Channel Blockers explode all trees</P>
<P>#18      muscle</P>
<P>#19      MeSH descriptor Muscles explode all trees</P>
<P>#20      MeSH descriptor Muscle Contraction explode all trees</P>
<P>#21      muscle AND contraction</P>
<P>#22      spinal AND cord</P>
<P>#23      neuromuscular AND junction</P>
<P>#24      MeSH descriptor Neuromuscular Junction explode all trees</P>
<P>#25      MeSH descriptor Neuromuscular Manifestations explode all trees</P>
<P>#26      motor AND endplate</P>
<P>#27      MeSH descriptor Motor Endplate explode all trees</P>
<P>#28      (#13 OR #14 OR #15 OR #16 OR #17)</P>
<P>#29      (#18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)</P>
<P>#30      (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)</P>
<P>#31      (#30 AND ( #28 AND #29 ))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-08-21 12:09:51 +0200" MODIFIED_BY="Deirdre Beecher" NO="2">
<TITLE MODIFIED="2008-08-21 12:08:01 +0200" MODIFIED_BY="Deirdre Beecher">MEDLINE (PubMed) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-21 12:09:51 +0200" MODIFIED_BY="Deirdre Beecher">
<P>(((("Multiple Sclerosis"[mh]) OR ("Myelitis, Transverse"[mh:noexp]) OR ("Demyelinating Diseases"[mh:noexp]) OR ("Encephalomyelitis, Acute Disseminated"[mh:noexp]) OR ("Optic Neuritis"[mh])) OR ((("multiple sclerosis") OR ("neuromyelitis optica") OR ("transverse myelitis") OR (encephalomyelitis) OR (devic) OR ("optic neuritis")) OR ("demyelinating disease*") OR ("acute disseminated encephalomyelitis"))) AND (((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT ((animals[mh]) NOT ((animals[mh]) AND (human[mh]))))) AND (((aminopyridine*) OR ("Aminopyridines"[Mesh]) OR (dap) OR (diaminopyridine) OR ("Potassium Channel Blockers"[Mesh]) OR (Potassium Channel Blockers)) AND ((MUSCLE) OR (muscle AND contraction) OR (spinal AND cord) OR ("Neuromuscular Junction"[Mesh]) OR (neuromuscular AND junction) OR ("Neuromuscular Manifestations"[Mesh]) OR ("Motor Endplate"[Mesh]) OR (Motor AND Endplate)))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-08-21 12:11:39 +0200" MODIFIED_BY="Deirdre Beecher" NO="3">
<TITLE MODIFIED="2008-08-21 12:08:17 +0200" MODIFIED_BY="Deirdre Beecher">EMBASE (EMBASE.com) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-21 12:11:39 +0200" MODIFIED_BY="Deirdre Beecher">
<P>((('encephalomyelitis'/exp) OR ('demyelinating disease'/exp) OR ('multiple sclerosis'/exp) OR ('myelooptic neuropathy'/exp) OR ('multiple sclerosis':ti,ab) OR ('neuromyelitis optica':ab,ti) OR (encephalomyelitis:ab,ti) OR (devic:ti,ab)) AND (('crossover procedure'/exp) OR ('double blind procedure'/exp) OR ('single blind procedure'/exp) OR ('clinical trial'/exp) OR ('randomized controlled trial'/exp) OR (random*:ab,ti) OR (factorial*:ab,ti) OR (crossover:ab,ti) OR (cross:ab,ti AND over:ab,ti) OR (placebo:ab,ti) OR ('double blind':ab,ti) OR ('single blind':ab,ti) OR (assign*:ab,ti) OR (allocat*:ab,ti) OR (volunteer*:ab,ti))) AND (('aminopyridine derivative'/exp) OR ('4 aminopyridine'/exp) OR (aminopyridein*:ab,ti OR dap:ab,ti OR diaminopyridine:ab,ti) OR ('potassium channel blocking agent'/exp)) AND ((muscle:ab,ti OR (muscle:ab,ti AND contraction:ab,ti) OR (spinal:ab,ti AND cord:ab,ti) OR (neuromuscular:ab,ti AND junction:ab,ti) OR 'motor endplate':ab,ti) OR ('muscle'/exp) OR ('muscle contraction'/exp) OR ('neuromuscular synapse'/exp) OR ('muscle disease'/exp) OR ('nerve ending'/exp)) AND [humans]/lim AND [embase]/lim</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>